Abstract

Objectives: To evaluate a staging system for vascular adverse events (VAEs) after facial fillers, distinguishing non-necrotic from necrotic cases, to identify anatomical areas with higher necrosis risk, and to define an appropriate treatment protocol by integrating staging interpretation, ultrasound imaging and insights into the diffusion barriers that limit hyaluronidase efficacy. Introduction: Vascular adverse events (VAEs) after facial fillers can present with a wide range of clinical patterns, leading to variability in recommended treatment protocols and outcomes. A clear, standardized staging system is essential to classify VAEs accurately, distinguish necrotic from non-necrotic cases, and guide consistent, evidence-based treatment worldwide. Materials / method: I retrospectively analyzed 120 VAEs (2019–2024) using a five-stage photographic system and three anatomical classification models. Additionally, 39 international VAEs (2022–2025) were treated via remote real-time ultrasound-guided hyaluronidase. Physiochemical data on hyaluronidase diffusion within HA fillers were reviewed. Results: Stages 1–2 were non-necrotic, stages 3–5 represented necrotic outcomes. Stage-3 pustules/blisters and necrotic outcomes did not always indicate bacterial infection. Necrosis occurred more frequently in the medial face (p=0.048). Remote ultrasound-guided treatment achieved 100% recovery with ~208 units hyaluronidase per patient, compared with >1500 units for blind injections. Diffusion barriers explained the frequent failure of blind techniques. Conclusion: The five-stage system enables injectors to recognize vascular adverse events (VAEs) after facial fillers and determine whether necrosis is present. Necrosis-like signs such as pustules do not necessarily indicate infection, questioning routine antibiotic use. Medial facial regions show higher necrosis risk. Ultrasound-guided hyaluronidase allows targeted, low-dose treatment and rapid recovery compared with blind injections, which fail due to diffusion limits. This integrated approach supports a consistent global standard for VAE management.